Another clinical marker, CDX2, has been implicated in chemotherapy responsiveness, with CDX2-negative CRC patients reportedly benefiting from chemotherapy, but not specifically from oxaliplatin [35]. The gene discussed is CDX2; the disease is colorectal carcinoma.